Publications by authors named "Paola Andrea Lopez Zapana"
Background: Respiratory syncytial virus is associated with significant neonatal and infant morbidity and mortality. Maternal bivalent respiratory syncytial virus prefusion F respiratory syncytial virus vaccination to protect neonates and infants was approved in September 2023 for administration between 32+0 and 36+6 weeks to protect neonates and infants. This approved timeframe is narrower than the 24 to 36 week window evaluated in the clinical trial, due to the possible association between preterm birth and vaccine administration.
View Article and Find Full Text PDFArticle Synopsis
- - The maternal bivalent RSVpreF vaccine was approved in September 2023 to protect infants from Respiratory Syncytial Virus, with a specific administration window due to concerns about preterm birth, although it's narrower than what was tested in clinical trials.
- - The study aims to investigate how the timing of the maternal vaccination affects the transfer of antibodies to the fetus and the resulting antibody levels in infants at two months old.
- - Conducted at two medical centers, the research compares antibody levels from vaccinated mothers and their infants to those from mothers who experienced natural RSV infections, using various testing methods to measure immunity.